Abbott Laboratories $ABT Shares Bought by Cox Capital Mgt LLC

Cox Capital Mgt LLC lifted its holdings in Abbott Laboratories (NYSE:ABT) by 72.3% during the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 28,525 shares of the healthcare product maker’s stock after acquiring an additional 11,971 shares during the quarter. Abbott Laboratories makes up approximately 1.6% of Cox Capital Mgt LLC’s holdings, making the stock its 21st largest holding. Cox Capital Mgt LLC’s holdings in Abbott Laboratories were worth $2,819,000 at the end of the most recent quarter.

Other large investors have also bought and sold shares of the company. BlackRock Inc. boosted its stake in Abbott Laboratories by 4.6% in the second quarter. BlackRock Inc. now owns 152,563,476 shares of the healthcare product maker’s stock worth $13,843,610,000 after purchasing an additional 6,769,518 shares in the last quarter. State Street Corp increased its stake in shares of Abbott Laboratories by 1.7% in the second quarter. State Street Corp now owns 80,926,234 shares of the healthcare product maker’s stock valued at $7,343,246,000 after buying an additional 1,350,766 shares in the last quarter. J. Stern & Co. LLP raised its holdings in shares of Abbott Laboratories by 12,439.6% in the fourth quarter. J. Stern & Co. LLP now owns 39,319,009 shares of the healthcare product maker’s stock valued at $4,926,279,000 after buying an additional 39,005,451 shares during the last quarter. T. Rowe Price Investment Management Inc. raised its holdings in shares of Abbott Laboratories by 0.7% in the fourth quarter. T. Rowe Price Investment Management Inc. now owns 17,887,109 shares of the healthcare product maker’s stock valued at $2,241,076,000 after buying an additional 118,014 shares during the last quarter. Finally, Bank of America Corp DE acquired a new position in Abbott Laboratories during the 2nd quarter worth about $1,603,607,000. 75.18% of the stock is currently owned by institutional investors.

Trending Headlines about Abbott Laboratories

Here are the key news stories impacting Abbott Laboratories this week:

• Positive Sentiment: Barclays initiated coverage with an “overweight” rating and a $120 price target, implying substantial upside from recent levels. The firm’s bullish view reflects growing confidence in Abbott’s medical-device and broader medtech exposure. Stryker, Abbott among overweight ideas as Barclays turns bullish on MedTech
• Positive Sentiment: Analyst research highlighted a bullish initiation on Abbott, adding to favorable sentiment around the shares. This Abbott Analyst Begins Coverage On A Bullish Note
• Positive Sentiment: Evercore ISI raised its price target to $124 from $120 while maintaining an “outperform” rating, signaling confidence in Abbott’s longer-term earnings potential. Evercore ISI Adjusts Price Target on Abbott Laboratories
• Positive Sentiment: Abbott introduced Ensure Max Protein 3-in-1 Muscle Support, combining protein, creatine, and HMB in one product. The launch expands its consumer-health offering and targets growing mainstream wellness demand, though the near-term financial effect is likely limited. Abbott introduces Ensure Max Protein 3-in-1 Muscle Support
• Neutral Sentiment: Commentary describes ABT as a potential dividend bargain following its 2026 decline. Abbott has made 411 consecutive quarterly dividend payments since 1924, appealing to income-focused investors, but the company is not currently showing rapid growth trends. Is Abbott Laboratories a Dividend Bargain After Its 2026 Selloff?
• Negative Sentiment: Abbott recently declined even as the broader market advanced, indicating continued stock-specific pressure and cautious investor sentiment. The pullback may improve dividend valuation, but it also reflects concerns about growth and near-term momentum. Abbott Stock Drops Despite Market Gains

Wall Street Analyst Weigh In

Several research firms have weighed in on ABT. Weiss Ratings upgraded shares of Abbott Laboratories from a “hold (c-)” rating to a “hold (c)” rating in a research report on Friday, September 18th. Bank of America reduced their target price on shares of Abbott Laboratories from $120.00 to $102.00 in a research report on Friday, June 12th. Wolfe Research raised shares of Abbott Laboratories from a “peer perform” rating to an “outperform” rating and set a $130.00 price target for the company in a report on Thursday, August 13th. Royal Bank Of Canada restated an “outperform” rating and issued a $130.00 price objective on shares of Abbott Laboratories in a research report on Friday, July 17th. Finally, JPMorgan Chase & Co. upped their price objective on Abbott Laboratories from $110.00 to $120.00 and gave the stock an “overweight” rating in a report on Friday, July 17th. Three analysts have rated the stock with a Strong Buy rating, twenty-one have assigned a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat.com, Abbott Laboratories presently has an average rating of “Moderate Buy” and an average target price of $118.88.

Abbott Laboratories Trading Up 0.5%

Abbott Laboratories stock traded up $0.54 during trading hours on Wednesday, reaching $98.70. 9,392,108 shares of the company’s stock traded hands, compared to its average volume of 11,346,689. The firm has a market capitalization of $170.79 billion, a price-to-earnings ratio of 31.94, a PEG ratio of 1.86 and a beta of 0.59. The company has a debt-to-equity ratio of 0.57, a quick ratio of 0.97 and a current ratio of 1.38. Abbott Laboratories has a fifty-two week low of $81.97 and a fifty-two week high of $135.13. The firm’s 50 day moving average is $106.52 and its 200-day moving average is $98.39.

Abbott Laboratories (NYSE:ABT) last issued its quarterly earnings results on Thursday, July 16th. The healthcare product maker reported $1.31 EPS for the quarter, topping the consensus estimate of $1.28 by $0.03. Abbott Laboratories had a net margin of 11.65% and a return on equity of 17.69%. The company had revenue of $12.59 billion during the quarter, compared to analysts’ expectations of $12.52 billion. During the same quarter in the previous year, the company earned $1.26 EPS. Abbott Laboratories’s revenue was up 13.0% on a year-over-year basis. Abbott Laboratories has set its Q3 2026 guidance at 1.380-1.46 EPS and its FY 2026 guidance at 5.450-5.60 EPS. On average, analysts predict that Abbott Laboratories will post 5.52 earnings per share for the current year.

Abbott Laboratories Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Shareholders of record on Thursday, October 15th will be given a dividend of $0.63 per share. The ex-dividend date is Thursday, October 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.6%. Abbott Laboratories’s payout ratio is presently 81.55%.

Abbott Laboratories Profile

Abbott Laboratories (NYSE:ABT) is a diversified healthcare company that develops, manufactures and sells medical devices, diagnostic products, nutritional products and branded generic pharmaceuticals. Founded in 1888 by Wallace C. Abbott, the company serves healthcare providers, institutions, retailers and consumers worldwide.

Abbott’s medical device portfolio includes cardiovascular products, such as coronary stents, structural heart systems and heart failure devices, as well as diabetes-care technologies, including the FreeStyle Libre continuous glucose monitoring system.